从对索托拉西布有出色反应的G12C突变肺腺癌发生的新发小细胞肺癌转化：一例报告
De Novo SCLC Transformation From G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report.
作者信息
Ito Takanori, Oi Issei, Saito Zentaro, Imakita Takuma, Kanai Osamu, Fujita Kohei, Tachibana Hiromasa, Moriyoshi Koki, Mio Tadashi
机构信息
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Division of Pathology, National Hospital Organisation Kyoto Medical Center, Kyoto, Japan.
出版信息
JTO Clin Res Rep. 2023 Mar 29;4(5):100510. doi: 10.1016/j.jtocrr.2023.100510. eCollection 2023 May.
The transformation to SCLC is a known mechanism of resistance against molecularly targeted therapies. This study reports a patient with untreated lung adenocarcinoma, characterized by a G12C mutation, which transformed into SCLC before treatment. Both the adenocarcinoma and SCLC components were responsive to sotorasib.
向小细胞肺癌（SCLC）的转化是一种已知的对分子靶向治疗产生耐药性的机制。本研究报告了一名未经治疗的肺腺癌患者，其特征为存在G12C突变，在治疗前转化为SCLC。腺癌和SCLC成分对索托拉西布均有反应。
Zotero 插件